LIVIVO - Search results -

Search results

Result 1 - 10 of total 118

Search options

Article: Concern about the Safety of Bisphenol A Substitutes.

Moon, Min Kyong

2019 Volume 43, Issue 1, Page(s) 46–48

MeSH term(s)	Benzhydryl Compounds/adverse effects ; Benzhydryl Compounds/chemistry ; Benzhydryl Compounds/pharmacology ; Biological Monitoring/standards ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/epidemiology ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/chemically induced ; Diabetes Mellitus, Type 2/epidemiology ; Epoxy Resins ; Estrogens, Non-Steroidal/adverse effects ; Estrogens, Non-Steroidal/chemistry ; Estrogens, Non-Steroidal/pharmacology ; Humans ; Obesity/blood ; Obesity/chemically induced ; Obesity/epidemiology ; Phenols/adverse effects ; Phenols/chemistry ; Phenols/pharmacology ; Polymers ; Reproductive Health/statistics & numerical data
Chemical Substances	Benzhydryl Compounds ; Epoxy Resins ; Estrogens, Non-Steroidal ; Phenols ; Polymers ; lexan (24936-68-3) ; bisphenol A (MLT3645I99)
Language	English
Publishing date	2019-02-21
Publishing country	Korea (South)
Document type	Editorial
ZDB-ID	2602402-0
ISSN	2233-6087 ; 2233-6079
ISSN (online)	2233-6087
ISSN	2233-6079
DOI	10.4093/dmj.2019.0027
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement.

Yang, Ye Seul / Kim, Hack-Lyoung / Kim, Sang-Hyun / Moon, Min Kyong

Journal of lipid and atherosclerosis

2023 Volume 12, Issue 1, Page(s) 12–22

Abstract: Dyslipidemia in patients with diabetes is an important treatment target as a modifiable risk factor for cardiovascular disease (CVD). Although the primary treatment goal for dyslipidemia is to control low-density lipoprotein cholesterol (LDL-C), ... ...

Abstract	Dyslipidemia in patients with diabetes is an important treatment target as a modifiable risk factor for cardiovascular disease (CVD). Although the primary treatment goal for dyslipidemia is to control low-density lipoprotein cholesterol (LDL-C), achieving this goal remains suboptimal according to recent studies. It is important to set the target goal for LDL-C control based on an accurate risk assessment for CVD. Here, we summarize the latest evidence on lipid management in patients with diabetes and present a consensus of the Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis on the treatment goals of LDL-C according to the duration of diabetes, presence of CVD, target organ damage, or major cardiovascular risk factors. In patients with type 2 diabetes mellitus (T2DM) and CVD, an LDL-C goal of <55 mg/dL and a reduction in LDL-C level by 50% or more from the baseline is recommended. For the primary prevention of CVD in patients with T2DM with a duration of diabetes ≥10 years, major cardiovascular risk factors, or target organ damage, an LDL-C goal of <70 mg/dL is recommended. In patients with T2DM with a duration of diabetes <10 years and no major cardiovascular risk factors, an LDL-C goal of <100 mg/dL is recommended.
Language	English
Publishing date	2023-01-17
Publishing country	Korea (South)
Document type	Journal Article ; Review
ZDB-ID	3016001-7
ISSN	2288-2561 ; 2287-2892
ISSN (online)	2288-2561
ISSN	2287-2892
DOI	10.12997/jla.2023.12.1.12
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement.

Yang, Ye Seul / Kim, Hack-Lyoung / Kim, Sang-Hyun / Moon, Min Kyong

Diabetes & metabolism journal

2023 Volume 47, Issue 1, Page(s) 1–9

Abstract	Dyslipidemia in patients with diabetes is an important treatment target as a modifiable risk factor for cardiovascular disease (CVD). Although the primary treatment goal for dyslipidemia is to control low-density lipoprotein cholesterol (LDL-C), achieving this goal remains suboptimal according to recent studies. It is important to set the target goal for LDL-C control based on an accurate risk assessment for CVD. Here, we summarize the latest evidence on lipid management in patients with diabetes and present a consensus of the Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis on the treatment goals of LDL-C according to the duration of diabetes, presence of CVD, target organ damage, or major cardiovascular risk factors. In patients with type 2 diabetes mellitus (T2DM) and CVD, an LDL-C goal of <55 mg/dL and a reduction in LDL-C level by 50% or more from the baseline is recommended. For the primary prevention of CVD in patients with T2DM with a duration of diabetes ≥10 years, major cardiovascular risk factors, or target organ damage, an LDL-C goal of <70 mg/dL is recommended. In patients with T2DM with a duration of diabetes <10 years and no major cardiovascular risk factors, an LDL-C goal of <100 mg/dL is recommended.
MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/epidemiology ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Atherosclerosis/epidemiology ; Atherosclerosis/prevention & control ; Dyslipidemias/complications ; Dyslipidemias/drug therapy ; Dyslipidemias/epidemiology ; Republic of Korea/epidemiology
Chemical Substances	Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
Language	English
Publishing date	2023-01-20
Publishing country	Korea (South)
Document type	Journal Article ; Review
ZDB-ID	2602402-0
ISSN	2233-6087 ; 2233-6087
ISSN (online)	2233-6087
ISSN	2233-6087
DOI	10.4093/dmj.2022.0448
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prevalence of Diabetic Retinopathy in Undiagnosed Diabetic Patients: A Nationwide Population-Based Study.

Jang, Han Na / Moon, Min Kyong / Koo, Bo Kyung

Diabetes & metabolism journal

2022 Volume 46, Issue 4, Page(s) 620–629

Abstract: Background: We investigated the prevalence of diabetic retinopathy (DR) in patients with undiagnosed diabetes through a nationwide survey, compared to those with known diabetes.: Methods: Among the participants of the Korean National Health and ... ...

Abstract	Background: We investigated the prevalence of diabetic retinopathy (DR) in patients with undiagnosed diabetes through a nationwide survey, compared to those with known diabetes. Methods: Among the participants of the Korean National Health and Nutrition Examination Surveys (KNHANES) from 2017 to 2018, individuals aged ≥40 years with diabetes and fundus exam results were enrolled. Sampling weights were applied to represent the entire Korean population. Newly detected diabetes patients through KNHANES were classified under "undiagnosed diabetes." Results: Among a total of 9,108 participants aged ≥40 years, 951 were selected for analysis. Of them, 31.3% (standard error, ±2.0%) were classified under "undiagnosed diabetes." The prevalence of DR in patients with known and undiagnosed diabetes was 24.5%±2.0% and 10.7%±2.2%, respectively (P<0.001). The DR prevalence increased with rising glycosylated hemoglobin (HbA1c) levels in patients with known and undiagnosed diabetes (P for trend=0.001 in both). Among those with undiagnosed diabetes, the prevalence of DR was 6.9%±2.1%, 8.0%±3.4%, 5.6%±5.7%, 16.7%±9.4%, and 42.6%±14.8% for HbA1c levels of <7.0%, 7.0%-7.9%, 8.0%-8.9%, 9.0%-9.9%, and ≥10.0% respectively. There was no difference in the prevalence of hypertension, dyslipidemia, hypertriglyceridemia, or obesity according to the presence or absence of DR. Conclusion: About one-third of patients with diabetes were unaware of their diabetes, and 10% of them have already developed DR. Considering increasing the prevalence of DR according to HbA1c level was found in patients with undiagnosed diabetes like those with known diabetes, screening and early detection of diabetes and DR are important.
MeSH term(s)	Diabetes Mellitus/diagnosis ; Diabetes Mellitus/epidemiology ; Diabetic Retinopathy/diagnosis ; Diabetic Retinopathy/epidemiology ; Glycated Hemoglobin A/analysis ; Humans ; Nutrition Surveys ; Prevalence ; Risk Factors
Chemical Substances	Glycated Hemoglobin A
Language	English
Publishing date	2022-02-23
Publishing country	Korea (South)
Document type	Journal Article
ZDB-ID	2602402-0
ISSN	2233-6087 ; 2233-6087
ISSN (online)	2233-6087
ISSN	2233-6087
DOI	10.4093/dmj.2021.0099
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Lipoprotein(a): a not-so-well-known risk factor for the development of cardiovascular disease in patients with type 2 diabetes mellitus.

Moon, Min Kyong

The Korean journal of internal medicine

2016 Volume 31, Issue 6, Page(s) 1061–1063

MeSH term(s)	Cardiovascular Diseases ; Cholesterol, HDL ; Diabetes Mellitus, Type 2 ; Humans ; Lipoprotein(a) ; Risk Factors
Chemical Substances	Cholesterol, HDL ; Lipoprotein(a)
Language	English
Publishing date	2016
Publishing country	Korea (South)
Document type	Editorial
ZDB-ID	639023-7
ISSN	2005-6648 ; 1226-3303
ISSN (online)	2005-6648
ISSN	1226-3303
DOI	10.3904/kjim.2016.301
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 3028: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Gene-diet interaction analysis using novel weighted food scores discovers the adipocytokine signaling pathway associated with the development of type 2 diabetes.

Apio, Catherine / Chung, Wonil / Moon, Min Kyong / Kwon, Oran / Park, Taesung

Frontiers in endocrinology

2023 Volume 14, Page(s) 1165744

Abstract: Introduction: The influence of dietary patterns measured using Recommended Food Score (RFS) with foods with high amounts of antioxidant nutrients for Type 2 diabetes (T2D) was analyzed. Our analysis aims to find associations between dietary patterns and ...

Abstract	Introduction: The influence of dietary patterns measured using Recommended Food Score (RFS) with foods with high amounts of antioxidant nutrients for Type 2 diabetes (T2D) was analyzed. Our analysis aims to find associations between dietary patterns and T2D and conduct a gene-diet interaction analysis related to T2D. Methods: Data analyzed in the current study were obtained from the Korean Genome and Epidemiology Study Cohort. The dietary patterns of 46 food items were assessed using a validated food frequency questionnaire. To maximize the predictive power of the RFS, we propose two weighted food scores, namely HisCoM-RFS calculated using the novel Hierarchical Structural Component model (HisCoM) and PLSDA-RFS calculated using Partial Least Squares-Discriminant Analysis (PLS-DA) method. Results: Both RFS (OR: 1.11; 95% CI: 1.03- 1.20; P = 0.009) and PLSDA-RFS (OR: 1.10; 95% CI: 1.02-1.19, P = 0.011) were positively associated with T2D. Mapping of SNPs (P < 0.05) from the interaction analysis between SNPs and the food scores to genes and pathways yielded some 12 genes (CACNA2D3, RELN, DOCK2, SLIT3, CTNNA2, etc.) and pathways associated with T2D. The strongest association was observed with the adipocytokine signalling pathway, highlighting 32 genes (STAT3, MAPK10, MAPK8, IRS1, AKT1-3, ADIPOR2, etc.) most likely associated with T2D. Finally, the group of the subjects in low, intermediate and high using both the food scores and a polygenic risk score found an association between diet quality groups with issues at high genetic risk of T2D. Conclusion: A dietary pattern of poor amounts of antioxidant nutrients is associated with the risk of T2D, and diet affects pathway mechanisms involved in developing T2D.
MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/genetics ; Antioxidants ; Diet ; Signal Transduction/genetics ; Adipokines
Chemical Substances	Antioxidants ; Adipokines
Language	English
Publishing date	2023-08-23
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2592084-4
ISSN	1664-2392
ISSN	1664-2392
DOI	10.3389/fendo.2023.1165744
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Muscle strength, an independent determinant of glycemic control in older adults with long-standing type 2 diabetes: a prospective cohort study.

Koo, Bo Kyung / Moon, Seoil / Moon, Min Kyong

BMC geriatrics

2021 Volume 21, Issue 1, Page(s) 684

Abstract: Background: Although the proportion of older patients with type 2 diabetes mellitus (T2DM) has increased, few studies have reported the factors affecting glucose levels in older patients with long-standing T2DM. This study assessed the determinants of ... ...

Abstract	Background: Although the proportion of older patients with type 2 diabetes mellitus (T2DM) has increased, few studies have reported the factors affecting glucose levels in older patients with long-standing T2DM. This study assessed the determinants of glycemic control in older adults with T2DM of a duration of ≥10 years, including muscle mass, muscle quality, and β-cell function. Methods: This was a prospective study of older patients aged ≥60 years with a T2DM duration of ≥10 years. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index, handgrip strength (HGS), and body composition through bioelectrical impedance analysis were assessed. The primary outcome was a composite of: (i) increment of glycated hemoglobin (HbA1c) from the baseline ≥0.6% and (ii) HbA1c ≥ 9% at any time point during the follow-up period. To find the predicting determinants of the outcome, we performed the Cox proportional hazard analysis. Results: Among 100 patients (mean age, 64.0 ± 8.6 years; median duration of diabetes, 20 [interquartile range (IQR), 17-23] years; median HbA1c at baseline, 7.1 [IQR, 6.7-7.4] %), the primary outcome was observed in 40 (40.0%) patients during 4.0 (IQR 2.3-5.0) years of follow-up. A Cox proportional hazards model adjusted for age, sex, baseline HbA1c, obesity, duration of DM and anti-diabetic medication at baseline showed that low HGS and insulin resistance at the baseline were independent determinants of the primary outcome (hazard ratio [HR] = 2.23 [95% confidence interval (CI), 1.06-4.72] and 2.39 [95% CI, 1.18-4.83], respectively). Sex stratification confirmed that HGS and muscle mass were independent determinants of the primary outcome only in women (HR per quartile, 0.58 [95% CI, 0.37-0.93] and 0.46 [95% CI, 0.25-0.85], respectively). `. Conclusions: Low HGS and insulin resistance were independent risk factors for aggravated glycemic control among older patients with long standing T2DM.
MeSH term(s)	Aged ; Blood Glucose ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Female ; Glycemic Control ; Hand Strength ; Humans ; Muscle Strength ; Prospective Studies
Chemical Substances	Blood Glucose
Language	English
Publishing date	2021-12-07
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2059865-8
ISSN	1471-2318 ; 1471-2318
ISSN (online)	1471-2318
ISSN	1471-2318
DOI	10.1186/s12877-021-02629-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: The clinical course of hospitalized COVID-19 patients and aggravation risk prediction models: a retrospective, multi-center Korean cohort study.

Moon, Min Kyong / Ham, Hyeonjung / Song, Soo Min / Lee, Chanhee / Goo, Taewan / Oh, Bumjo / Lee, Seungyeoun / Kim, Shin-Woo / Park, Taesung

Frontiers in medicine

2024 Volume 10, Page(s) 1239789

Abstract: Background: Understanding the clinical course and pivotal time points of COVID-19 aggravation is critical for enhancing patient monitoring. This retrospective, multi-center cohort study aims to identify these significant time points and associate them ... ...

Abstract	Background: Understanding the clinical course and pivotal time points of COVID-19 aggravation is critical for enhancing patient monitoring. This retrospective, multi-center cohort study aims to identify these significant time points and associate them with potential risk factors, leveraging data from a sizable cohort with mild-to-moderate symptoms upon admission. Methods: This study included data from 1,696 COVID-19 patients with mild-to-moderate clinical severity upon admission across multiple hospitals in Daegu-Kyungpook Province (Daegu dataset) between February 18 and early March 2020 and 321 COVID-19 patients at Seoul Boramae Hospital (Boramae dataset) collected from February to July 2020. The approach involved: (1) identifying the optimal time point for aggravation using survival analyses with maximally selected rank statistics; (2) investigating the relationship between comorbidities and time to aggravation; and (3) developing prediction models through machine learning techniques. The models were validated internally among patients from the Daegu dataset and externally among patients from the Boramae dataset. Results: The Daegu dataset showed a mean age of 51.0 ± 19.6 years, with 8 days for aggravation and day 5 being identified as the pivotal point for survival. Contrary to previous findings, specific comorbidities had no notable impact on aggravation patterns. Prediction models utilizing factors including age and chest X-ray infiltration demonstrated promising performance, with the top model achieving an AUC of 0.827 in external validation for 5 days aggravation prediction. Conclusion: Our study highlights the crucial significance of the initial 5 days period post-admission in managing COVID-19 patients. The identification of this pivotal time frame, combined with our robust predictive models, provides valuable insights for early intervention strategies. This research underscores the potential of proactive monitoring and timely interventions in enhancing patient outcomes, particularly for those at risk of rapid aggravation. Our findings offer a meaningful contribution to understanding the COVID-19 clinical course and supporting healthcare providers in optimizing patient care and resource allocation.
Language	English
Publishing date	2024-01-04
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2775999-4
ISSN	2296-858X
ISSN	2296-858X
DOI	10.3389/fmed.2023.1239789
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study).

Kim, Hae Jin / Noh, Jung Hyun / Moon, Min Kyong / Choi, Sung Hee / Ko, Seung-Hyun / Rhee, Eun-Jung / Hur, Kyu Yeon / Jeong, In-Kyung

Journal of diabetes research

2024 Volume 2024, Page(s) 8915591

Abstract: Background: We aimed to compare efficacy and safety between gemigliptin add-on and escalation of the metformin dose in patients with inadequately controlled type 2 diabetes mellitus (T2DM) despite treatment with metformin and SGLT2 inhibitors.: ... ...

Abstract	Background: We aimed to compare efficacy and safety between gemigliptin add-on and escalation of the metformin dose in patients with inadequately controlled type 2 diabetes mellitus (T2DM) despite treatment with metformin and SGLT2 inhibitors. Methods: This study was a multicenter, randomized, open-label, active-controlled, parallel-group comparative study. Patients with T2DM uncontrolled on metformin and SGLT2 inhibitors were randomized to receive gemigliptin 50 mg as an add-on (GEM group, Results: At weeks 12 and 24, the reduction in HbA1c levels was significantly greater in the GEM group than in the MET group (GEM vs. MET = -0.64% ± 0.34% vs. -0.36% ± 0.50%, Conclusions: Gemigliptin add-on therapy may be more effective than metformin dose escalation in patients with T2DM insufficiently controlled using metformin and SGLT2 inhibitors, without safety concerns. This trial is registered with CRIS_number: KCT0003520.
MeSH term(s)	Humans ; Blood Glucose ; Diabetes Mellitus, Type 2/drug therapy ; Double-Blind Method ; Drug Therapy, Combination ; Glycated Hemoglobin ; Glycemic Control ; Hypoglycemic Agents/administration & dosage ; Metformin/administration & dosage ; Piperidones ; Pyrimidines ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Treatment Outcome
Chemical Substances	Blood Glucose ; Glycated Hemoglobin ; Hypoglycemic Agents ; LC15-0444 ; Metformin (9100L32L2N) ; Piperidones ; Pyrimidines ; Sodium-Glucose Transporter 2 Inhibitors
Language	English
Publishing date	2024-01-05
Publishing country	England
Document type	Randomized Controlled Trial ; Multicenter Study ; Journal Article
ZDB-ID	2711897-6
ISSN	2314-6753 ; 2314-6753
ISSN (online)	2314-6753
ISSN	2314-6753
DOI	10.1155/2024/8915591
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study.

Koo, Bo Kyung / Chung, Woo-Young / Moon, Min Kyong

Cardiovascular diabetology

2020 Volume 19, Issue 1, Page(s) 82

Abstract: Background: Reactive hyperemia-peripheral arterial tonometry (RH-PAT) is a noninvasive and simple test for evaluating the endothelial function. There has been sparse evidence on the usefulness of the RH-PAT index (RHI) in predicting future ... ...

Abstract	Background: Reactive hyperemia-peripheral arterial tonometry (RH-PAT) is a noninvasive and simple test for evaluating the endothelial function. There has been sparse evidence on the usefulness of the RH-PAT index (RHI) in predicting future cardiovascular diseases among diabetic patients. Methods: Asymptomatic diabetic patients with albuminuria were selected; their medical history and laboratory findings were evaluated every 3 to 4 months, respectively. The primary outcome was a composite of three-point major adverse cardiovascular events (3-point MACE): death from cardiovascular causes, acute coronary events, or nonfatal stroke. On the contrary, secondary outcomes included a composite of 3-point MACE, hospitalization for heart failure, or chronic kidney disease (CKD) progression. RHI was measured using the Endo-PAT2000 at the baseline. RHI < 1.67 was considered to indicate peripheral endothelial dysfunction (PED). Results: In total, 149 subjects were included (mean age, 61.8 ± 9.2 years; duration of diabetes was 12 years). During the follow-up period (median, 49.7 months), of the 149 subjects, primary outcomes were detected in 12 (1 [2.3%] and 11 [10.5%] of those without and with PED, respectively). The presence of PED in baseline measurements significantly increased both primary and secondary outcomes, following adjustment for age, sex, hypertension, glycated hemoglobin, low-density lipoprotein cholesterol, triglyceride, systolic blood pressure, baseline estimated glomerular filtration rate, overt proteinuria, duration of diabetes, premedical history of ischemic events, anti-platelet agents, and smoking history (hazard ratio [HR]: 10.95; 95% confidence interval CI 1.00-119.91 for the primary outcome; HR, 4.12; 95% CI 1.37-12.41 for secondary outcome). In addition, PED could predict secondary outcomes independent of the risk score according to the American College of Cardiology/American Heart Association (HR: 3.24; 95% CI 1.14-9.17). Conclusions: PED can independently predict future cardiovascular events among diabetic patients with albuminuria.
MeSH term(s)	Aged ; Albuminuria/diagnosis ; Albuminuria/epidemiology ; Albuminuria/mortality ; Albuminuria/therapy ; Diabetic Nephropathies/diagnosis ; Diabetic Nephropathies/epidemiology ; Diabetic Nephropathies/mortality ; Endothelium, Vascular/physiopathology ; Female ; Humans ; Hyperemia/physiopathology ; Male ; Manometry ; Middle Aged ; Peripheral Arterial Disease/diagnosis ; Peripheral Arterial Disease/mortality ; Peripheral Arterial Disease/physiopathology ; Peripheral Arterial Disease/therapy ; Predictive Value of Tests ; Prevalence ; Prognosis ; Prospective Studies ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/epidemiology ; Renal Insufficiency, Chronic/mortality ; Renal Insufficiency, Chronic/therapy ; Risk Assessment ; Risk Factors ; Seoul/epidemiology ; Time Factors
Language	English
Publishing date	2020-06-13
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1475-2840
ISSN (online)	1475-2840
DOI	10.1186/s12933-020-01062-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED